DiagnoCure's GCC marker for the staging of colorectal cancer discussed at two scientific meetings



    First sales of the Previstage(TM) GCC test confirmed

    Ticker Symbol: CUR

    QUEBEC CITY, Sept. 25 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, announced today that its Guanylyl Cyclase C
(GCC) marker for identifying colorectal cancer cells is being featured at
two scientific meetings this month. The Company also announced that its
wholly-owned subsidiary, DiagnoCure Oncology Laboratories, had received its
first orders of its new Previstage(TM) GCC Colorectal Cancer Staging Test and
is now delivering test results to physicians.

    GCC marker presented at major conferences

    The GCC marker, for which DiagnoCure owns exclusive worldwide diagnostic
rights, is being featured in two scientific meetings this month. Dr. Scott
Waldman, from Thomas Jefferson University, who first identified the relation
of the GCC gene to colorectal cells, is presenting his research work and
discussing the applications of molecular diagnostics to cancer management.
    Dr. Waldman's work was recognized at this year's Molecular Diagnostics in
Cancer Therapeutics Conference. This important conference is devoted to the
latest developments in the integration of molecular diagnostics with cancer
drug development and patient treatment. Aspects of GCC lymph node testing were
presented to the attendees coming from the industry, academic institutions and
the government, as well as patient-advocacy groups and regulatory agencies.
Also, on September 24, as part of the same meeting, Dr. Waldman participated
in a local media roundtable entitled Molecular Diagnostics: Leading the World
from Philadelphia.
    In addition, on September 29, at the Biomarker Discovery Summit,
Dr. Waldman will be chairing and presenting selected GCC lymph node testing
research data in a pre-conference workshop entitled: Novel Approaches to
Cancer Biomarkers.

    First orders of Previstage(TM) GCC received

    Following on the research work of Dr. Waldman, DiagnoCure developed the
Previstage(TM) GCC Colorectal Cancer Staging Test, and launched the test at
the end of August 2008. The Company reports that physicians have started to
order the test and are now sending lymph nodes removed during colorectal
surgery to be tested with Previstage(TM) GCC for the presence of GCC. "This is
a very positive first response to the launch of our test. For the moment, we
have a small sales team focusing on educating the market and getting our first
sales. We will continue to introduce Previstage(TM) GCC at meetings, present
new data and expand the team as required. We are confident that our
disciplined launch and management will help us achieve commercial success,"
stated John Schafer, President and CEO of DiagnoCure.

    About Previstage(TM) GCC

    Every year in North America, 174,000 people are diagnosed with colorectal
cancer, and 142,000 colorectal cancer surgeries are performed. Staging a
patient with colorectal cancer is crucial because it determines the patient's
course of treatment after the surgery. Current standard of care requires that
pathologists microscopically examine a thin slice of tissue from each of the
lymph nodes harvested during the patient's surgery to see if cancer has
spread. Currently, up to 25 - 30 percent of patients with no
pathologically-positive lymph nodes (stage I and II cancers) later develop
recurrent disease, presumably through occult metastases that have escaped
detection. Most of these patients do not receive additional therapies such as
chemotherapy. With a detection capacity that is close to 100,000 more
sensitive than microscopic methods, Previstage(TM) GCC provides clinicians
with significantly more accurate information for staging a patient with
colorectal cancer that will increase their confidence in making critical
treatment decisions.
    Clinical study data supports the potential for the GCC test to improve
the current staging of colorectal patients. The National Cancer Institute
sponsored a five-year prospective clinical trial of GCC testing in colorectal
cancer patients. This study has been recently completed and the Company's
collaborators at Thomas Jefferson University are presenting the results at
major medical conferences throughout the year.
    The Previstage(TM) GCC Colorectal Cancer Staging Test is a
laboratory-developed test and its performance characteristics have been
determined by DiagnoCure Oncology Laboratories.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. The
Company also has a strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the
development and commercialization of a second-generation prostate cancer test
using PCA3, DiagnoCure's proprietary molecular marker. This test is also
available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.




For further information:

For further information: Investors: DiagnoCure Inc.: J.F. Bureau, CFA,
Sr. Vice President and CFO, (418) 527-6100, communications@diagnocure.com;
Media: U.S.: Troy Pearson, Mentus Life Science, (858) 455-5500 X320,
Troy@mentus.com; Canada: Jean-Pierre Trudel, Jean-Pierre Trudel & Associates,
(514) 347-6111, jp.trudel@videotron.ca; Clinicians: DiagnoCure Oncology
Laboratories: Customer Care, 1-877-701-9007, customercare@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890